- Press Release -

Rockville, Md. The global blood cancer diagnostics market is set to grow at a 6.4% CAGR through 2022, according to Fact.MR, as better testing methods and steady research spending widen the options available to clinicians. Diagnostics span established blood counts through to newer molecular techniques, and the mix is shifting as evidence builds behind less invasive approaches.

Blood testing and hospital laboratories anchor the market, the United States leads by revenue, and liquid biopsy stands out as the method gaining ground fastest.

Test Types and End Users

The complete blood count, or CBC, is currently worth nearly US$ 77 Mn and is expected to grow at close to 5% CAGR, holding a significant share of revenue in North America. Blood testing more broadly stays in wide use thanks to its accuracy, while liquid biopsy is gaining momentum on the back of research, including work at the Massachusetts General Hospital Cancer Center and Harvard Medical School showing its value for patients with advanced cholangiocarcinoma. Bone marrow testing also remains widely used for its diagnostic reliability, with revenue expected to grow at a healthy rate.

Among end users, hospital-associated labs account for a significant share and are set to grow at over 6% CAGR, with independent diagnostic laboratories expanding at a similar pace and demand also strong from cancer research institutes.

Research Investment Drives Demand

The market leans heavily on innovation. Leading companies are investing in research to develop more accurate diagnostic solutions, and the United States remains pivotal thanks to its research base and steady flow of new developments. In Europe, Germany and the United Kingdom account for meaningful revenue, supported by R&D and a rising incidence of blood cancers.

Suppliers and Their Playbook

The field brings together diagnostics majors and specialist molecular testing firms.

• Abbott Laboratories, Thermo Fisher Scientific Inc., Roche Holding A.G., Laboratory Corporation of America Holdings, Luminex Corporation, NanoString Technologies Inc, Myriad Genetics Inc., NeoGenomics Laboratories, Inc., Quest Diagnostics Incorporated, Siemens AG, Qiagen N.V., Biotheranostics, Inc, Agilent Technologies, Almac Group Limited, and GeneNews Limited are among the key players profiled in the report.

Mergers, acquisitions and collaborations remain a recurring theme as firms build out their diagnostic portfolios.

Reading the Market for Decisions

For diagnostics firms, molecular methods such as liquid biopsy and strong hospital-lab relationships are the clearest routes to growth. Investors get a market with dependable, research-led demand. Procurement and clinical teams can plan around blood testing leading current volume, hospital labs dominating end use, and the United States carrying the largest share through 2022.

About the Report

Fact.MR's study covers the global blood cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user and region. It examines each segment, maps the competitive field, and weighs the research and clinical forces shaping demand. Further detail is available in the blood cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.